Advisory Services Network LLC Has $1 Million Stock Position in United Therapeutics Co. (NASDAQ:UTHR)

Advisory Services Network LLC boosted its holdings in shares of United Therapeutics Co. (NASDAQ:UTHR) by 172.3% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 2,835 shares of the biotechnology company’s stock after buying an additional 1,794 shares during the quarter. Advisory Services Network LLC’s holdings in United Therapeutics were worth $1,000,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently bought and sold shares of the business. Newbridge Financial Services Group Inc. acquired a new stake in shares of United Therapeutics during the 4th quarter worth about $25,000. Millstone Evans Group LLC acquired a new stake in United Therapeutics during the fourth quarter worth approximately $67,000. MassMutual Private Wealth & Trust FSB boosted its holdings in shares of United Therapeutics by 31.9% during the fourth quarter. MassMutual Private Wealth & Trust FSB now owns 240 shares of the biotechnology company’s stock worth $85,000 after acquiring an additional 58 shares during the period. Jones Financial Companies Lllp grew its position in shares of United Therapeutics by 678.9% in the fourth quarter. Jones Financial Companies Lllp now owns 296 shares of the biotechnology company’s stock valued at $104,000 after purchasing an additional 258 shares during the last quarter. Finally, SBI Securities Co. Ltd. bought a new position in United Therapeutics during the 4th quarter worth $131,000. Institutional investors own 94.08% of the company’s stock.

Insiders Place Their Bets

In related news, Director Raymond Dwek sold 4,000 shares of the firm’s stock in a transaction on Monday, April 7th. The stock was sold at an average price of $284.55, for a total transaction of $1,138,200.00. Following the sale, the director now owns 1,750 shares of the company’s stock, valued at $497,962.50. This trade represents a 69.57 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, EVP Paul A. Mahon sold 11,000 shares of the company’s stock in a transaction dated Thursday, April 3rd. The stock was sold at an average price of $306.18, for a total value of $3,367,980.00. Following the completion of the transaction, the executive vice president now directly owns 36,781 shares of the company’s stock, valued at approximately $11,261,606.58. The trade was a 23.02 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 77,500 shares of company stock valued at $26,994,480. 11.90% of the stock is currently owned by insiders.

United Therapeutics Stock Up 0.8 %

NASDAQ:UTHR opened at $281.16 on Monday. United Therapeutics Co. has a twelve month low of $230.39 and a twelve month high of $417.82. The stock’s 50-day simple moving average is $323.22 and its 200 day simple moving average is $351.09. The firm has a market capitalization of $12.63 billion, a PE ratio of 12.35, a price-to-earnings-growth ratio of 0.97 and a beta of 0.63.

United Therapeutics (NASDAQ:UTHR) last posted its quarterly earnings results on Wednesday, February 26th. The biotechnology company reported $6.19 earnings per share for the quarter, beating analysts’ consensus estimates of $6.10 by $0.09. The company had revenue of $735.90 million for the quarter, compared to the consensus estimate of $734.74 million. United Therapeutics had a net margin of 40.31% and a return on equity of 19.22%. During the same period last year, the company posted $4.36 EPS. On average, analysts anticipate that United Therapeutics Co. will post 24.48 EPS for the current fiscal year.

Wall Street Analyst Weigh In

UTHR has been the topic of a number of analyst reports. StockNews.com lowered shares of United Therapeutics from a “strong-buy” rating to a “buy” rating in a research report on Thursday, February 27th. HC Wainwright restated a “buy” rating and set a $425.00 price objective on shares of United Therapeutics in a research note on Thursday, February 27th. Finally, UBS Group upped their target price on United Therapeutics from $415.00 to $475.00 and gave the company a “buy” rating in a research report on Wednesday, January 8th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and ten have assigned a buy rating to the company. According to data from MarketBeat, United Therapeutics presently has an average rating of “Moderate Buy” and an average target price of $388.25.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.